Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: A retrospective database study
References (25)
- et al.
Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: A retrospective data analysis in Germany
Clin Ther
(2006) - et al.
Global and societal implications of the diabetes epidemic
Nature
(2001) - et al.
Revealing the cost of type II diabetes in Europe
Diabetologia
(2002) - et al.
Epidemiology of insulin-treated diabetes mellitus in the East-German population: Differences in long-term trends between incidence and prevalencerates
Diabete Metab.
(1993) Prevalence of diabetes mellitus in the adult German population [in German]
Gesundheitswesen
(1999)- et al.
Complications; comorbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany—results from the CODE-2 study
Exp Clin Endocrinol Diabetes
(2002) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
N Engl J Med
(1993)Intensive blood-glucose control with sulphonylureas or in-sulin compared with conventional treatment and risk of complications in patients withtype 2 diabetes (UKPDS 33)
Lancet
(1998)Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Lancet
(1998)Management of type 2 diabetes: Management of blood glucose
(September 2002)
A desktop guide to type 2 diabetes mellitus
Diabet Med
Evaluation of risk factors for development of complications in type II diabetes in Europe
Diabetologia
Cited by (61)
Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000–2018
2019, Primary Care DiabetesCitation Excerpt :The European countries surveyed by Overbeek et al. [21] reported sulfonylureas to be the second most commonly prescribed drug class across all countries however this study also reported a decrease in the use of sulfonylureas in the Europe (2008–2012). In Spain (2009) [23] and Germany (2004 to 2010) [24] sulfonylureas were reported to be prescribed for about 17% and 12% of patients, respectively. Filion et al. [25] reported a decrease in the number of patients receiving sulfonylurea prescriptions in the period 2000 to 2006.
Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus
2017, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Some pathogenic mechanisms, including chronic hyperglycemia, acute hypoglycemic episodes, microvascular disease, inflammation, obesity, and dyslipidemia, have been reported (Ninomiya, 2014; Cereda et al., 2011; Sridhar et al., 2015). Because most patients with T2DM ultimately receive oral antidiabetic drugs (OADs) (Yurgin et al., 2007; Sharma et al., 2016; Oishi et al., 2014), investigating the effects of antidiabetic medications on the development of dementia and PD is necessary. Metformin, an orally active biguanide, is inexpensive and well tolerated.
Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents
2017, Journal of the American Medical Directors AssociationFixed-dose combination therapy in type 2 diabetes mellitus
2014, Endocrine PracticeCitation Excerpt :Furthermore, met-formin is contraindicated in patients with T2DM who have significant renal dysfunction and in patients with metabolic acidosis (21-23). Despite adverse effects and contraindications, met-formin is the most commonly prescribed antihyperglyce-mic medication for patients with T2DM (24-26). Indeed, among FDCs currently available for T2DM, those containing metformin (Tables 1 and 2) far outnumber those not containing metformin (Table 3).
Glycemic control among patients with type 2 diabetes at a primary health care center in Oman
2014, Primary Care DiabetesCitation Excerpt :A large multi-center study conducted in seven European countries found that only 26% of out-patients with type 2 DM had adequate glycaemic control (HbA1c < 6.5%) and that glycaemic control modestly declined over time, even though more patients were being treated with insulin [5]. Furthermore, studies conducted in the UK, Germany, UAE and Venezuela found that the prevalence of inadequate glycaemic control was >60%, >50%, 69% and 76%; respectively [14–17]. In our study, we found that older patients controlled their blood sugar more efficiently than younger patients but the correlation was not statistically significant (Table 1).
Sex differences in cardiovascular outcomes, pharmacological treatments and indicators of care in patients with newly diagnosed diabetes: Analyses on administrative database
2014, European Journal of Internal Medicine